{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    10,
    12,
    16,
    21,
    31,
    36,
    41,
    45,
    48
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_4",
        "affectedSection": "Section 3.5, 5.3.1.1, 5.4.1, 5.7, 6.1.6, 9.2, 9.3",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added benefits and risks evaluation and updated study procedures in the context of the COVID-19 pandemic."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.1, 5.3.1.1, Appendix F",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Introduced off-site phone visit options for subjects on stable long-term single-agent therapy."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.3.1.1",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Modified tumor assessment schedule and central review requirements following primary analysis."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.3.5, 8.1.8",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Discontinued IDMC reviews as the primary analysis has occurred."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.3.3, 8.1",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Reclassified Duration of Response (DOR) from a secondary to a tertiary endpoint."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_4",
        "reasonText": "To allow for procedure modification in response to the COVID-19 pandemic and confirm benefit-risk profile remains unchanged.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_4",
        "reasonText": "To add flexibility for subjects on study long term while maintaining standard of care monitoring.",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_4",
        "reasonText": "Primary analysis was completed on 03 June 2019, making separate unblinded management teams and certain central reviews unnecessary.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_4",
        "reasonText": "To limit cumulative radiation exposure for patients with long-term disease control and align with standard of care.",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_5",
        "amendmentId": "amend_4",
        "reasonText": "To clarify the reporting period for adverse events of special interest with delayed onset (MDS/AML).",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.3.1.1",
        "beforeText": "every 9 weeks from C1D-2",
        "afterText": "every 12 weeks from last scan... must not exceed 24 weeks",
        "summary": "Updated tumor assessment schedule to allow for longer intervals between scans after primary analysis."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.3.3",
        "beforeText": "secondary endpoint",
        "afterText": "tertiary endpoint",
        "summary": "Changed Duration of Response (DOR) classification to align with the Statistical Analysis Plan."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_4",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.5",
        "beforeText": "null",
        "afterText": "reporting of myelodysplastic syndrome, acute myeloid leukemia, or any secondary primary malignancy",
        "summary": "Added specific reporting requirements for AESIs with potential delayed onset."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_4",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "Global",
        "beforeText": "Blinded/Unblinded TA MD and study teams",
        "afterText": "null",
        "summary": "Removed references to separate blinded/unblinded sponsor teams following the primary analysis unblinding."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_4",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "Appendix F",
        "beforeText": "null",
        "afterText": "Study Activities for Blinded or Unblinded Study Treatment Phone Visit",
        "summary": "Added a new appendix and table of assessments for off-site phone visits."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 5,
      "changeCount": 5
    }
  }
}